There was an increase in quarterly prescription rates from 4.2% in July to September 2021 to 23.5% in July to September 2023. (HealthDay News) — From 2021 to 2023, there was an increase in ...
(HealthDay News) — Exposure to certain antiseizure medications (ASMs) in utero is associated with an increased likelihood of neurodevelopmental diagnoses, according to a study published online Nov. 15 ...
The Food and Drug Administration (FDA) has approved Attruby TM (acoramidis) for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to ...
According to the Company, detailed results will be presented at a medical meeting in 2025. A phase 3 trial evaluating tiragolumab in combination with Tecentriq ® (atezolizumab) in adults with PD-L1 ...
Simufilam is an investigational oral small molecule that targets the filamin A protein. In the ReThink-ALZ study (ClinicalTrials.gov Identifier: NCT04994483 ), patients with confirmed mild or moderate ...
Participants were randomly assigned to receive subcutaneous sotatercept or placebo every 21 days with background PAH therapy. The primary endpoint was the time to first confirmed morbidity or ...
Imkeldi is a liquid formulation of imatinib that utilizes proprietary technology to allow for accurate dosing and an alternative formulation to tablets.